Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 15,49 € (+65,31%). La mediana è 15,49 € (+65,31%).
| Acquista |
9 |
| Mantieni |
3 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
evoke confirms 2025 outlook with expected revenue growth and strong EBITDA margin
evoke plc has confirmed its revenue growth forecast for the 2025 financial year at 5-9% and expects an adjusted EBITDA margin of at least 20%, which is above current market consensus. For the first half of 2025, adjusted EBITDA is projected at £163 to £167 million, an increase of 43% compared to the previous year. The forecasts meet or exceed current market expectations and estimates from Jefferies. » Altro su de.investing.com
Evoke plc director Andrea Gisle Joosen takes supervisory board position at Atlantic Grupa
Evoke plc announced that Andrea Gisle Joosen, independent non-executive director, will join the supervisory board of Atlantic Grupa as of September 4, 2025. The appointment was disclosed in accordance with UK stock exchange regulations. Further details regarding her role at Atlantic Grupa have not been released. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | set 2025 | |
|---|---|---|
| Ricavi | 3,65 Mln | - |
| Utile lordo | 3,56 Mln | - |
| Utile netto | -985,24K | - |
| EBITDA | -877,85K | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 16,31 Mln € |
Numero di azioni | 1,72 Mln |
Massimo/minimo a 52 settimane | 9,47 € - 1,67 € |
| Dividendi | No |
Beta | -0,14 |
Rapporto P/E | -6,96 |
Rapporto PEG | -0,04 |
Rapporto P/B | 8,37 |
Rapporto P/S | 1,70 |
Profilo aziendale
Evoke Pharma, Inc. ist ein Spezialpharmaunternehmen, das sich in erster Linie auf die Entwicklung und Vermarktung von Arzneimitteln zur Behandlung von gastroenterologischen Störungen und Krankheiten konzentriert. Das Unternehmen entwickelt Gimoti, ein Metoclopramid-Nasenspray, das klinische Studien der Phase 3 zur Behandlung von Symptomen im Zusammenhang mit akuter und wiederkehrender diabetischer Gastroparese bei Frauen abgeschlossen hat. Das Unternehmen vertreibt seine Produkte an Gastroenterologen, Fachärzte für innere Medizin, Hausärzte und ausgewählte Gesundheitsdienstleister. Evoke Pharma, Inc. wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in Solana Beach, Kalifornien.
| Nome | EVOKE PHARMA INC |
| CEO | Mark A. Kowieski |
| Sede centrale | Solana Beach,
ca Stati Uniti |
| Sito web | |
| Industria | Prodotti chimici |
| Quotazione in borsa | 25/09/2013 |
| Dipendenti | 3 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | EVOK |
Frankfurt | EV00.F |
Düsseldorf | EV00.DU |
München | EV00.MU |
Scopri gli asset
Gli azionisti di EVOKE PHARMA INC investono anche nei seguenti asset
